NCT00511095View on ClinicalTrials.gov

Open-Label Study of the Safety and Immunogenicity of HEPLISAV™ Hepatitis B Virus Vaccine

PHASE2CompletedINTERVENTIONAL
Enrollment

207

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

October 31, 2007

Study Completion Date

March 31, 2008

Conditions
Hepatitis B
Interventions
BIOLOGICAL

HEPLISAV

Intramuscular (IM) injections 0.5mL on Day 0 and Week 4

Trial Locations (7)

15217

Pediatric Alliance Southwestern, Pittsburgh

15241

Primary Physicians Research, Pittsburgh

Family Practice Medical Associates South, Upper Saint Clair

15301

The Washington Hospital Family Medicine, Washington

16127

Family Healthcare Partners, Grove City

22031

Metropolitan Research, Fairfax

44512

Beeghley Medical Park, Boardman

Sponsors
All Listed Sponsors
lead

Dynavax Technologies Corporation

INDUSTRY

NCT00511095 - Open-Label Study of the Safety and Immunogenicity of HEPLISAV™ Hepatitis B Virus Vaccine | Biotech Hunter | Biotech Hunter